# A Study of Modified mRNA Vaccines in Healthy Adults

> **NCT05397223** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 308 (actual)

## Conditions studied

- SARS-CoV-2
- Seasonal Influenza
- Respiratory Syncytial Virus
- Cytomegalovirus

## Interventions

- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** mRNA-1010
- **BIOLOGICAL:** mRNA-1345
- **BIOLOGICAL:** FLUAD®
- **BIOLOGICAL:** mRNA-1647

## Key facts

- **NCT ID:** NCT05397223
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-24
- **Primary completion:** 2026-02-27
- **Final completion:** 2026-02-27
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397223, "A Study of Modified mRNA Vaccines in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05397223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*